- Home
- CBIO vs MIY Comparison
CBIO vs MIY Comparison
Compare CBIO & MIY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBIO
- MIY
- Stock Information
- Founded
- CBIO 2003
- MIY 1992
- Country
- CBIO United States
- MIY United States
- Employees
- CBIO N/A
- MIY N/A
- Industry
- CBIO
- MIY Investment Bankers/Brokers/Service
- Sector
- CBIO
- MIY Finance
- Exchange
- CBIO Nasdaq
- MIY Nasdaq
- Market Cap
- CBIO 308.0M
- MIY 312.2M
- IPO Year
- CBIO N/A
- MIY N/A
- Fundamental
- Price
- CBIO $12.60
- MIY $10.84
- Analyst Decision
- CBIO Strong Buy
- MIY
- Analyst Count
- CBIO 3
- MIY 0
- Target Price
- CBIO $25.67
- MIY N/A
- AVG Volume (30 Days)
- CBIO 138.8K
- MIY 56.8K
- Earning Date
- CBIO 08-23-2025
- MIY 01-01-0001
- Dividend Yield
- CBIO N/A
- MIY 3.98%
- EPS Growth
- CBIO N/A
- MIY N/A
- EPS
- CBIO N/A
- MIY N/A
- Revenue
- CBIO N/A
- MIY N/A
- Revenue This Year
- CBIO N/A
- MIY N/A
- Revenue Next Year
- CBIO N/A
- MIY N/A
- P/E Ratio
- CBIO N/A
- MIY N/A
- Revenue Growth
- CBIO N/A
- MIY N/A
- 52 Week Low
- CBIO $11.06
- MIY $9.45
- 52 Week High
- CBIO $21.40
- MIY $11.70
- Technical
- Relative Strength Index (RSI)
- CBIO N/A
- MIY 45.11
- Support Level
- CBIO N/A
- MIY $10.62
- Resistance Level
- CBIO N/A
- MIY $11.36
- Average True Range (ATR)
- CBIO 0.00
- MIY 0.13
- MACD
- CBIO 0.00
- MIY 0.02
- Stochastic Oscillator
- CBIO 0.00
- MIY 34.18
About CBIO Crescent Biopharma Inc. Common Stock
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
About MIY Blackrock MuniYield Michigan Quality Fund Inc.
Blackrock Muniyield Michigan Quality Fund Inc is a closed end fund. Its investment objective is to provide shareholders with as high a level of current income exempt from U.S. federal income taxes and New York State and New York City personal income taxes as is consistent with its investment policies and prudent investment management.